2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N2506
    Ginsenoside Ra1 83459-41-0 99.88%
    Ginsenoside Ra1 is a component from ginseng, inhibits protein tyrosine kinase (PTK) activation induced by hypoxia/reoxygenation.
    Ginsenoside Ra1
  • HY-N2555
    Tilianin 4291-60-5 99.67%
    Tilianin is an active flavonoid glycoside found in many medical plants, with potential anti-hypertensive, myocardial-protective, anti-diabetic, anti-hyperlipidemic, anti-inflammatory and antioxidant effects.
    Tilianin
  • HY-N3807
    Enniatin B1 19914-20-6
    Enniatin B1 is a Fusarium mycotoxin. Enniatin B1 inhibits acyl-CoA: cholesterol acyltransferase (ACAT) activity with an IC50 of 73 μM in an enzyme assay using rat liver microsomes. Enniatin B1 crosss the blood-brain barrier. Enniatin B1 decreases the activation of ERK (p44/p42). Enniatin B1 inhibits moderately TNF-α-induced NF-κB activation.
    Enniatin B1
  • HY-N3961
    Neoglycyrol 23013-84-5 99.20%
    Neoglycyrol is isolated from the root of Glycyrrhiza uralensis Fisch. Neoglycyrol is a potential myocardial protection active compound screened from traditional patent medicine Tongmai Yangxin pill (TMYXP).
    Neoglycyrol
  • HY-N4195
    Resveratroloside 38963-95-0 99.88%
    Resveratroloside (Resveratrol glycoside) is a competitive inhibitior of α-glucosidase with an IC50 of 22.9 μM. Resveratroloside has the ability to regulate PBG (postprandial blood glucose) levels. Resveratroloside exhibits cardioprotective effect.
    Resveratroloside
  • HY-N7127
    (E)-m-Coumaric acid 14755-02-3 99.74%
    (E)-m-Coumaric acid (3-Hydroxycinnamic acid) is an aromatic acid that highly abundant in food. (E)-m-Coumaric acid (3-Hydroxycinnamic acid) is an antioxidant.
    (E)-m-Coumaric acid
  • HY-N7395
    Cyclic ADP-​ribose 119340-53-3
    Cyclic ADP-ribose (cADPR) is a potent second messenger for calcium mobilization that is synthesized from NAD+ by an ADP-ribosyl cyclase. Cyclic ADP-ribose increases cytosolic calcium mainly by Ryanodine receptor-mediated release from endoplasmic reticulum and also by extracellular influx through the opening of TRPM2 channels.
    Cyclic ADP-​ribose
  • HY-P1000
    TRAP-14 137339-65-2 98.02%
    TRAP-14 (SFLLRNPNDKYEPF) is a synthetic thrombin receptor agonist peptide.
    TRAP-14
  • HY-P3395
    Catestatin (human) 197151-46-5 99.46%
    Catestatin human, a catecholamine release-inhibitory peptide, is a pleiotropic peptide involved in cardiovascular protection with its antihypertensive and angiogenic effects. Catestatin human can be used in the study of inflammatory diseases .
    Catestatin (human)
  • HY-P9987
    Crizanlizumab 1690318-25-2
    Crizanlizumab is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease.
    Crizanlizumab
  • HY-100713
    Temocapril 111902-57-9
    Temocapril is an orally active angiotensin-converting enzyme (ACE) inhibitor. Temocapril can be used for the research of hypertension, congestive heart failure, acute myocardial infarction, insulin resistance, and renal diseases.
    Temocapril
  • HY-101054
    NQ301 130089-98-4 98.98%
    NQ301 is an antithrombotic agent; inhibits collagen-challenged rabbit platelet aggregation with an IC50 of 10 mg/mL.
    NQ301
  • HY-101862
    CB-7921220 115453-99-1 ≥98.0%
    CB-7921220 is an adenylate cyclase inhibitor.
    CB-7921220
  • HY-103239
    PT1 331002-70-1 99.13%
    PT1 is an AMPKα1 activator that directly activates the inactive truncated forms of AMPKα1 monomers.
    PT1
  • HY-103460
    IRL 2500 169545-27-1 ≥99.0%
    IRL 2500 is a potent Endothelin receptor antagonist. IRL 2500 shows IC50 values of 1.3 and 94 nM for ETB and ETA receptors, respectively. IRL 2500 inhibits ETB receptor-mediated blood pressure increase and renal vascular resistance in rats in vivo.
    IRL 2500
  • HY-106130
    Implitapide 177469-96-4 99.87%
    Implitapide (AEGR 427) is a microsomal triglyceride transfer protein (MTP) inhibitor.
    Implitapide
  • HY-107580
    GPR109 receptor agonist-1 306935-41-1 99.91%
    GPR109 receptor agonist-1 (Compound 3a) is a highly selective agonist of the human orphan G-protein-coupled receptor GPR109b, with the pEC50 of 6.4. GPR109 receptor agonist-1 can be used for the research of cardio-metabolic diseases.
    GPR109 receptor agonist-1
  • HY-108760
    Gadoterate meglumine 92943-93-6 99.86%
    Gadoterate meglumine (Gd-DOTA) is a non-specific paramagnetic gadolinium complex used as a contrast enhancer in magnetic resonance imaging (MRI). Gadoterate meglumine, as a contrast agent in MRI, is able to shorten the longitudinal relaxation time (T1) of tissue, resulting in a brighter signal in MRI images. Gadoterate meglumine can be used for the study of the central nervous system (such as the brain and spinal cord), abdominal, pelvic organs, breast, bone and joint imaging, angiography, and cardiac electrophysiology.
    Gadoterate meglumine
  • HY-113042
    Prostaglandin B2 13367-85-6 ≥99.0%
    Prostaglandin B2 is a prostaglandin. Prostaglandin B2 is the main substance in cord blood mesenchymal stem cells, to inhibit DC-T Cell proliferation. Prostaglandin B2 also induces cutaneous vasoconstriction of the canine hind paw.
    Prostaglandin B2
  • HY-117743
    Eprosartan 133040-01-4 99.87%
    Eprosartan (SKF-108566J free base) is a selective, competitive, nonpeptid and orally active angiotensin II receptor antagonist, used as an antihypertensive. Eprosartan binds angiotensin II receptor with IC50s of 9.2 nM and 3.9 nM in rat and human adrenal cortical membranes, respectively .
    Eprosartan
Cat. No. Product Name / Synonyms Application Reactivity